Effect of Moxifloxacin Combined with Imipenem and Cilastatin Sodium on Elderly Patients with Severe Pneumonia
Objective To investigate the effects of moxifloxacin combined with imipenem and cilastatin sodium on lung function,inflammatory factor levels and clinical symptom resolution time in elderly patients with severe pneumonia.Methods The clinical data of 120 patients with severe pneumonia admitted to Guiyang Public Health Clinical Center from January 2022 to August 2023 were retrospectively analyzed.According to the different treatment methods,they were divided into a control group and an observation group,with 60 cases in each group.The control group was treated with imipenem and cilastatin sodium,and the observation group was treated with moxifloxacin combined with imipenem and cilastatin sodium,both groups were treated continuously for 10 days.The clinical symptom resolution time,lung function and inflammatory factor levels were compared between the two groups.Results In the observation group,the time for high fever to disapppearance was(4.68±0.92)d,the time for pulmonary rale to disappear was(5.36±0.73)d,the time for cough to disappear was(5.41±0.86)d,and the time for dyspnea to disappear was(4.89±0.77)d,which were shorter than(7.24±1.06)d,(8.11±1.46)d,(7.94±1.33)d and(6.83±1.63)d in the control group,and the differences between the groups were statistically significant(P<0.05).After treatment,the Forced Expiratory Volume for one second and forced vital capacity of the observation group were(2.85±0.22)L and(3.05±0.33)L,which were higher than(2.39±0.27)L and(2.52±0.28)L of the control group,and the peak expiratory flow was(2.98±0.36)L/s,which was higher than(2.55±0.28)L/s of the control group,and the differences between the groups were statistically significant(P<0.05);in the observation group,hypersensitive C-reactive protein was(6.53±2.14)mg/L,erythrocyte sedimentation rate(21.32±6.93)mm/H,interleukin-6 was(11.71±3.36)pg/mL,and tumor necrosis factor-α was(18.85±3.16)pg/mL,which were lower than(8.43±1.13)mg/L,(23.45±6.43)mm/H,(14.70±4.48)pg/mL,(23.00±5.20)pg/mL of the control group,and the differences between the groups were statistically significant(P<0.05).Conclusion Compared with imipenem and cilastatin sodium,moxifloxacin combined with moxifloxacin can effectively reduce the level of inflammatory factors,relieve clinical symptoms and improve lung function in the treatment of senile severe pneumonia.
Severe pneumoniaMoxifloxacinImipenem and cilastatin sodiumLung functionInflammatory response
万方数据
